Cerebral Pricing Analysis & Total Cost: What You Actually Pay in 2025

How Much Does Cerebral Cost? A Full Plan-by-Plan Breakdown

Cerebral uses a subscription model that bundles clinician access into monthly flat fees rather than charging per visit. The base charge covers a set number of live sessions; anything beyond that tier costs extra. Understanding what each tier actually includes is the most direct way to compare true cost.

The Three Core Plans

Therapy Only ($99/month). This plan pairs you with a licensed therapist for one 45-minute video session per month. Additional sessions cost roughly $59 each. There is no prescriber access on this plan, so you cannot receive a prescription through Cerebral without upgrading.

Medication Management + Care Counseling ($195/month). A prescribing clinician (physician, NP, or PA) conducts an intake assessment and follow-up visits. A care counselor, not a licensed therapist, provides supplemental check-ins. Care counselors hold bachelor's or master's degrees but are not independently licensed to provide psychotherapy. This distinction matters clinically. The American Psychiatric Association's 2023 telepsychiatry guidelines explicitly differentiate licensed psychotherapy from care management support, noting that "care coordination does not substitute for evidence-based psychotherapy delivered by a licensed mental health professional." [1]

Medication + Therapy ($325/month approximately). This combines the prescriber visits with licensed therapy sessions. It is the most comprehensive plan and the one most closely approximating a traditional outpatient psychiatric care model.

What Insurance Covers

Cerebral accepts most major commercial insurers, including Aetna, Cigna, United Healthcare, and Blue Cross Blue Shield networks, plus Medicaid in a subset of states. When insurance applies, the monthly subscription fee is replaced by standard copays, typically $20 to $50 per visit depending on your plan design. The medication cost itself is handled separately through your pharmacy benefit.

Patients should verify in-network status before enrolling. Cerebral has faced past network-status disputes; a 2022 report by the Wall Street Journal documented billing irregularities that led to insurer audits in multiple states. [2]

Hidden Costs to Factor In

Monthly subscription fees do not include:

• Prescription drug costs (paid at pharmacy, subject to your formulary)
• Lab work if ordered (e.g., thyroid panel for mood disorders, CMP for medication monitoring)
• Out-of-network fees if your insurer later reclassifies a Cerebral clinician
• Cancellation window: missing the 24-hour cancellation window triggers a late-cancel fee ($50, $75 depending on session type)

Is Cerebral Legit? Regulatory History and Clinical Standards

Cerebral is a licensed telehealth platform operating in all 50 states. It is not a scam. The clinical concerns that have been raised publicly center on prescribing practices, regulatory scrutiny, and care quality consistency, not on whether the company delivers services at all.

DEA Investigation and Stimulant Prescribing

In 2022, the DEA and the Department of Justice opened an investigation into Cerebral's prescribing of controlled stimulants, specifically amphetamine salts and methylphenidate for ADHD. [3] Federal law under the Ryan Haight Online Pharmacy Consumer Protection Act historically required an in-person evaluation before any Schedule II substance could be prescribed via telemedicine. [4] The COVID-19 public health emergency temporarily waived that requirement; Cerebral grew rapidly under that waiver.

Post-PHE rules issued by the DEA in 2023 and finalized in 2024 now require either a prior in-person visit or registration with a specialized telemedicine prescriber registry for Schedule II stimulants. [5] Cerebral announced in 2023 that it would no longer prescribe Schedule II stimulants (Adderall, Ritalin) for new patients without prior in-person evaluation, which aligns with the updated federal framework. Patients seeking stimulant ADHD treatment through Cerebral today should confirm current prescribing policy at time of enrollment, because the regulatory field shifted materially between 2022 and 2025.

Non-stimulant ADHD medications, including atomoxetine (Strattera) and viloxazine (Qelbree), are not Schedule II substances and remain prescribable via telehealth under standard rules. [6]

State Medical Board Oversight

Cerebral's prescribers hold state licenses and are subject to standard board oversight. The platform itself must comply with state telehealth practice acts, which vary considerably. Some states prohibit prescribing controlled substances via telemedicine entirely regardless of federal waivers. Patients in states like Arkansas and Alabama have had reduced access to certain medication classes through Cerebral as a result.

Care Counselor vs. Therapist: A Clinical Distinction

As noted above, the $195/month plan's "care counselors" are not licensed therapists. This matters because major depression and generalized anxiety disorder have strong evidence bases specifically for licensed psychotherapy modalities. Cognitive behavioral therapy (CBT) for major depressive disorder achieves response rates of 43 to 65 percent in head-to-head trials. [7] Care counseling as Cerebral defines it has not been studied at equivalent rigor. Patients with moderate-to-severe depression or anxiety should weigh whether the $195 plan provides the licensed therapeutic contact their condition warrants.

What Cerebral Prescribes: Medications by Condition

Depression and Anxiety

Cerebral prescribers can prescribe the full formulary of non-controlled antidepressants and anxiolytics. Common options include:

• SSRIs: sertraline (Zoloft), escitalopram (Lexapro), fluoxetine (Prozac)
• SNRIs: venlafaxine (Effexor XR), duloxetine (Cymbalta)
• Other: bupropion (Wellbutrin), buspirone (Buspar)

The FDA-approved indication for sertraline in major depressive disorder is well established; a 2018 network meta-analysis in The Lancet (N=116,477, 21 antidepressants) found all studied agents statistically superior to placebo, with escitalopram and sertraline showing favorable efficacy-acceptability profiles. [8] Cerebral's prescribers operate within the same evidence base as any outpatient psychiatrist for these medications.

ADHD

As discussed above, Schedule II stimulant access is restricted. Non-stimulant options remain available. Atomoxetine has FDA approval for ADHD in adults and children; a 2019 Cochrane review (32 trials, N=5,765) found atomoxetine significantly reduced ADHD symptom scores versus placebo, though with smaller effect sizes than stimulants. [9]

Insomnia and Other Conditions

Cerebral treats insomnia and in select cases OCD, with prescribers able to offer medications including hydroxyzine, trazodone, and mirtazapine for sleep. Benzodiazepines (Schedule IV) are subject to more caution; Cerebral's stated policy limits long-term benzodiazepine initiation for new patients.

Cerebral vs. Alternatives: Cost and Clinical Comparison

Cerebral vs. Traditional In-Person Psychiatry

The average cash-pay cost for an initial psychiatric evaluation in the United States runs $300 to $500, with follow-up visits at $150 to $300, per FAIR Health consumer data. [10] A patient seeing a psychiatrist monthly and a therapist biweekly could spend $800 to $1,400 per month uninsured. Cerebral's $325 combined plan represents significant cost reduction for uninsured patients, assuming the platform meets their clinical needs.

The tradeoff: in-person psychiatrists can build longer-term relationships, conduct physical assessments, and in some states prescribe a broader range of controlled substances without the telehealth-specific restrictions.

Cerebral vs. BetterHelp

BetterHelp offers therapy only, starting at approximately $240 to $360 per month for weekly sessions. BetterHelp has no prescribing capability. Cerebral's $99 therapy-only plan is cheaper per session if you need only monthly contact, but BetterHelp's model typically includes weekly messaging plus sessions, which some patients find more supportive. BetterHelp also settled a $7.8 million FTC action in 2023 over sharing user health data with advertisers, a material privacy consideration. [11]

Cerebral vs. Talkiatry

Talkiatry is an insurance-only psychiatry platform that matches patients with board-certified psychiatrists (MDs and DOs) rather than NPs and PAs. Talkiatry does not offer a self-pay option. For insured patients seeking prescriber continuity with a physician-level clinician, Talkiatry may offer stronger clinical depth; for uninsured patients, it is not accessible.

Cerebral vs. Done (ADHD-Specific)

Done Health specializes in ADHD and charges $199 for an initial assessment plus $79/month. Done faced its own DEA scrutiny in 2022 related to stimulant prescribing [3], and similarly restricted Schedule II prescribing for new patients post-PHE. For ADHD-focused treatment at cash-pay rates, the cost structures of Done and Cerebral's medication plan are roughly comparable.

Cerebral Reviews: What Patient and Clinical Evidence Shows

Reported Outcomes

Controlled outcome data specific to Cerebral's patient population have not been published in peer-reviewed journals as of this writing. This is a genuine evidence gap. Cerebral has released internal satisfaction metrics on its website, but proprietary company data cannot be independently verified.

What the broader telehealth literature shows is instructive. A 2022 JAMA Psychiatry analysis of 1,686 patients found that synchronous video-based psychiatric care produced equivalent 12-week depression outcomes to in-person care on the PHQ-9 scale (mean difference 0.2 points, 95% CI -0.8 to 1.2). [12] This supports the telehealth model generally, though it does not validate Cerebral specifically.

Patient Satisfaction Patterns

Across aggregated third-party review platforms (Trustpilot, Google, BBB), Cerebral's ratings cluster around 3.0 to 3.5 out of 5. Common positive themes include fast access (first appointment within a week), convenient scheduling, and affordable cash-pay pricing. Common complaints center on care counselor quality, difficulty reaching prescribers between sessions, billing disputes, and abrupt clinician turnover.

The BBB has logged over 400 complaints against Cerebral since 2021, predominantly related to billing and cancellation disputes. This volume warrants caution, though the company's scale (reportedly over 200,000 patients at peak) provides important context for complaint rates.

Clinician Workforce Considerations

A 2022 investigative report by Stat News documented that Cerebral had a high turnover rate among its prescribing clinicians, with some patients reporting three or more prescriber changes within a single year. [13] Continuity of prescriber relationship is clinically meaningful for psychiatric medication management; the APA's Practice Guidelines for Major Depressive Disorder specifically cite therapeutic alliance as a predictor of medication adherence. [14]

Is Cerebral Worth It? A Structured Clinical Assessment

Whether Cerebral is worth the cost depends on which of three patient profiles best fits your situation.

Profile 1: Uninsured patient with mild-to-moderate depression or anxiety. Cerebral's $195 plan with an SSRI prescription may provide genuine value. The medications themselves are inexpensive generics (sertraline 100mg, 30-count: roughly $10 at GoodRx pricing). Access to a prescriber within a week beats the median 25-day wait for a new outpatient psychiatry appointment reported by the AAMC. [15] If you also add licensed therapy at the $325 tier, cost per month remains below most uninsured in-person equivalents.

Profile 2: Insured patient with access to in-network psychiatry. The cost advantage shrinks substantially. Your copay for an in-person psychiatrist may be comparable to or lower than Cerebral's copay after insurance, and you gain prescriber continuity and potential for in-person assessment. Worth running the numbers on your specific plan before defaulting to Cerebral.

Profile 3: Patient requiring Schedule II stimulants for ADHD. Cerebral is not a reliable pathway for new-patient stimulant prescribing under current DEA rules. Seeking an in-person evaluation with a psychiatrist or ADHD specialist who can then coordinate telehealth follow-up is the more direct route.

The National Institute of Mental Health estimates that 57% of American adults with a mental illness receive no treatment in a given year, largely due to cost and access barriers. [16] Platforms like Cerebral reduce those barriers for profiles 1 and 3 (for non-stimulant ADHD treatment). The access argument is real, and it carries measurable public health weight.

A 2021 Health Affairs study found that telehealth mental health visits increased 38-fold between February and April 2020 and sustained a 13-fold increase through 2021, with retention in care improving versus pre-telehealth baseline among Medicaid enrollees. [17] That population-level finding does not guarantee quality at the individual platform level, but it contextualizes why telehealth mental health services have clinical justification beyond mere convenience.

The most clinically appropriate use of Cerebral is as an access bridge for patients who would otherwise receive no care, not as a replacement for comprehensive psychiatric evaluation when that evaluation is accessible.